Bristol Myers Gets CHMP Backing for Opdualag in Advanced Melanoma
22 July 2022 - 9:51PM
Dow Jones News
By Colin Kellaher
Bristol Myers Squibb Co. on Friday said the European Medicines
Agency's Committee for Medicinal Products for Human Use recommended
approval of its cancer treatment Opdualag for certain advanced
melanoma patients.
The New York biopharmaceutical company said the recommendation
covers the first-line treatment of unresectable or metastatic
melanoma in patients 12 years of age and older with tumor cell
PD-L1 expression < 1%.
The European Commission, which generally follows CHMP's advice,
will now review the recommendation.
The U.S. Food and Drug Administration in March approved
Opdualag, a combination of Bristol's blockbuster cancer drug Opdivo
and its LAG-3-blocking antibody relatlimab, for patients 12 and
older with unresectable or metastatic melanoma, the most serious
type of skin cancer.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
July 22, 2022 07:36 ET (11:36 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Apr 2024 to May 2024
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From May 2023 to May 2024